Genes and pathways identified could inform new approaches to treatment and address acute need for drug development for this disorder. As part of a multinational, collaborative effort, researchers from the Icahn School of Medicine at Mount Sinai have helped identify over 100 locations in the human genome associated with the risk of developing schizophrenia, in the largest genomic study published on any psychiatric disorder to date, conducted with 80,000 people. The findings, published online in Nature, point to biological mechanisms and pathways that may underlie schizophrenia, and could lead to new approaches to treating the disorder, which has seen little innovation in drug development in more than 60 years.
|
No comments:
Post a Comment